Nuclear export inhibitors with anti-tumoral and anti-viral activity
Regulated nucleo-cytoplasmic transport of pathobiologically relevant proteins is critical for tumor development and viral diseases. Transport is mediated by nuclear export signals (NESs) interacting with the export receptor CRM1. NESs have been identified in numerous disease relevant cellular and viral proteins. Hence, the pharmacogenetic interference with nuclear export provides an attractive and novel therapeutic principle to rationally control and target the activity of such disease factors. This invention now provides three novel nuclear export inhibitors (NEIs) with shown anti-tumoral and antiviral activity. As such, these drugs may represent a hitherto neglected additional pillar for combination treatment of human diseases.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
